TempraMed Technologies Ltd.

TempraMed Technologies Ltd. (CNSX:VIVI) (FRA:9DY) is a global leader in innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered, space-grade thermal insulation hassle-free devices that work 24/7 for years without charging or external power. With a proven product line including VIVICap and VIVIEpi, and a smart technology platform on the horizon, TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime. With operations in North America, Europe, and Asia, TempraMed is advancing the future of medication protection and adherence.

 
    
 

View in Other Languages

News

TempraMed Technologies Ltd. (CNSX:VIVI) Exclusive Commercial Distribution Agreement with Turkish Medical Device Supplier

🕔12/2/2025 12:01:38 PM 3316

TempraMed Technologies Ltd. (CNSX:VIVI) (FRA:9DY) announced that it has entered into a definitive exclusive distribution agreement with Dolfin Saglik Urunleri ("Dolfin Saglik") to market and sell TempraMed's "VIVI" line of medication temperature-stabilizing products throughout Turkey.

Read Full Article
###

1,581 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 24) (Last 30 Days: 154) (Since Published: 901) 

Company Data

    Headquarters
  • 504-9300 Parksville Drive
    Richmond, BC V7E 4W2
    Canada
  • Telephone
  • +1-604-833-6820 
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Healthcare 
  • Homepage
  • https://www.tempramed.com

More News Results

  • 2026/01/14: TempraMed Receives Positive Response on Payor Reimbursement Model Driving Significant Return on Investment for Medical Payor Coverage*
  • 2026/01/12: TempraMed Closes C$2.5 Million Fully Subscribed Private Placement*
  • 2026/01/06: TempraMed Receives First Commercial Order from Israel Distributor and Completes Initial Shipment Enabling Entry into National Pharmacy Network*
  • 2026/01/02: TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026*
  • 2025/12/31: TempraMed Deepens Asian Market Penetration with Expanded Distribution Partnership and Meaningful Commercial Order in South Korea*
  • 2025/12/26: TempraMed Launches New Product, VIVI Cap Smart, Expanding Its Portfolio to Include a Digital Health Offering*
  • 2025/12/17: TempraMed Expands U.S. Manufacturing Capacity with New Production Facility in Florida*
  • 2025/12/15: TempraMed Strengthens Global Intellectual Property Position with Grant of South Korean Patent*
  • 2025/12/10: TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board*
  • 2025/12/08: TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients*
*refer to company website

Social Media